Faeth Therapeutics develops oral cancer therapeutics designed to inhibit multiple nodes of the PAM pathway. The company was acquired by Sensei Biotherapeutics in February 2026.
Faeth Therapeutics develops oral cancer therapeutics designed to inhibit multiple nodes of the PAM pathway. The company was acquired by Sensei Biotherapeutics in February 2026.